Ketamine, Esketamine and Depression

In October 2019, the U.S. Food and Drug Administration (FDA) approved esketamine, a substance chemicallyrelated to the party drug ketamine, as a nasal spray to treat depression (Bahr, 2019). The effectiveness of ketamine for depression was first shown in studies in...

The History of Aromatherapy: How Aromas Improve Mental Health

In recent years, the global aromatherapy market size was valued at $1.07 billion yearly, according to an industry analysis report for 2014 to 2025 published by Grand View Research. This lucrative growth shows no sign of stopping. Rising awareness about the therapeutic...